Julian Harrison
Stock Analyst at BTIG
(3.19)
# 2,729
Out of 4,983 analysts
44
Total ratings
50%
Success rate
3.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $15.35 | +356.03% | 3 | Sep 16, 2025 | |
| MAZE Maze Therapeutics | Maintains: Buy | $30 → $37 | $23.92 | +54.68% | 3 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reiterates: Buy | $32 | $6.34 | +404.73% | 1 | Sep 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Buy | $112 | $83.43 | +34.24% | 2 | Sep 9, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $13.97 | +79.02% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $10.61 | +277.18% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $9.80 | +328.57% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $16.08 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $19.96 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.07 | +741.12% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $1.87 | +327.81% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.30 | +2,540.26% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $61 | $19.00 | +221.05% | 3 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.84 | +91.33% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $26.38 | -5.23% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $60.51 | -15.72% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $37.52 | +14.61% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $2.83 | +41.34% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $1.71 | +8,671.93% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $52.52 | -31.45% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $399.98 | - | 2 | Feb 11, 2022 |
Spyre Therapeutics
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $15.35
Upside: +356.03%
Maze Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $23.92
Upside: +54.68%
Cullinan Therapeutics
Sep 10, 2025
Reiterates: Buy
Price Target: $32
Current: $6.34
Upside: +404.73%
ABIVAX Société Anonyme
Sep 9, 2025
Reiterates: Buy
Price Target: $112
Current: $83.43
Upside: +34.24%
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $13.97
Upside: +79.02%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $10.61
Upside: +277.18%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $9.80
Upside: +328.57%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $16.08
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $19.96
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.07
Upside: +741.12%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.87
Upside: +327.81%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.30
Upside: +2,540.26%
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $19.00
Upside: +221.05%
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.84
Upside: +91.33%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $26.38
Upside: -5.23%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $60.51
Upside: -15.72%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $37.52
Upside: +14.61%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $2.83
Upside: +41.34%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $1.71
Upside: +8,671.93%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $52.52
Upside: -31.45%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $399.98
Upside: -